Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists

Canadian Journal of Cardiology

Volumn 34, Issue 1, 2018, Pages 92.e1-92.e3

  Frigeri, Mauro ^a   Meyer, Philippe ^a   Banfi, Carlo ^a   Giraud, Raphaël ^a   Hachulla, Anne Lise ^a   Spoerl, David ^a   Friedlaender, Alex ^a   Pugliesi Rinaldi, Angela ^a   Dietrich, Pierre Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; INOTROPIC AGENT; METHYLPREDNISOLONE; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; TROPONIN; ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ANTICOAGULANT THERAPY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CLOTTING DISORDER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOGENIC SHOCK; CARDIOLOGIST; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CLINICAL ARTICLE; COMPLETE HEART BLOCK; CONTRAST ENHANCEMENT; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CRACKLE; DISEASE COURSE; DRUG INDUCED DISEASE; DYSPNEA; EXTRACORPOREAL OXYGENATION; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; INTENSIVE CARE UNIT; LEG EDEMA; LOWER LIMB; LUNG ADENOCARCINOMA; METASTASIS; MYOCARDITIS; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; BLOOD; EDEMA; IMMUNOLOGY;

ADENOCARCINOMA OF LUNG; AGED; ANTINEOPLASTIC AGENTS; EDEMA; FEMALE; HEART FAILURE; HUMANS; MYOCARDITIS; NATRIURETIC PEPTIDE, BRAIN; NIVOLUMAB; PEPTIDE FRAGMENTS; SHOCK, CARDIOGENIC; TROPONIN;

EID: 85039950523     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2017.09.025     Document Type: Article

References (5)

1. Johnson, D.B., Balko, J.M., Compton, M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
2. Tarrio, M.L., Grabie, N., Bu, D.X., et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188 (2012), 4876–4884.
3. Boutros, C., Tarhini, A., Routier, E., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13 (2016), 473–486.
4. Haanen, J.B.A.G., Carbonnel, F., Robert, C., et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:suppl 4 (2017), iv119–iv142.
5. Weber, J.S., Hodi, F.S., Wolchok, J.D., et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35 (2017), 785–792.